2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis
Adarsh Bhimraj, Yngve Falck–Ytter, Arthur Y Kim, Jonathan Z. Li, Lindsey R. Baden, Steven C. Johnson, Robert W. Shafer, Shmuel Shoham, Pablo Tebas, Roger Bedimo, Vincent Chi‐Chung Cheng, Kara W Chew, Kathleen Chiotos, Eric S. Daar, Amy Dzierba, David V. Glidden, Erica Hardy, Greg S. Martin, Christine E. MacBrayne, Nandita R. Nadig, Mari Nakamura, Amy Hirsch Shumaker, Phyllis C. Tien, Jennifer Loveless, Rebecca L. Morgan, Rajesh T. Gandhi
Abstract
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019, developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of the anti-severe acute respiratory syndrome coronavirus 2 neutralizing antibody pemivibart as pre-exposure prophylaxis. The recommendation is based on evidence derived from a systematic review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Information on pemivibart is included in the U.S. Food and Drug Administration Emergency Use Authorization for this agent.